Clinical evidence for oral antiplatelet therapy in acute coronary syndromes (Q38380465)

2 September 2017

1 reference

title

Clinical evidence for oral antiplatelet therapy in acute coronary syndromes (English)

1 reference

2 September 2017

Philippe Gabriel Steg

series ordinal

2

object named as

Philippe Gabriel Steg

0 references

author name string

Stephen D Wiviott

series ordinal

1

1 reference

PubMed ID

25777663

2 September 2017

language of work or name

English

0 references

publication date

14 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

386

1 reference

2 September 2017

9990

1 reference

2 September 2017

292-302

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Vorapaxar in the secondary prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

1 reference

7 January 2021

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Variability in platelet responsiveness to clopidogrel among 544 individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

1 reference

7 January 2021

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in My

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

1 reference

7 January 2021

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Effect of platelet inhibition with cangrelor during PCI on ischemic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Gro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960213-6

7 January 2021

10.1016/S0140-6736(15)60213-6

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25777663